ELP6: A Potential Drug Target and Biomarker (G54859)

Target Name: ELP6

NCBI ID: G54859

ELP6

ELP6: A Potential Drug Target and Biomarker

Epigenetic programming plays a crucial role in the development and maintenance of cellular processes. Epigenetic modifiers, such as DNA methylation, histone modification, and non-coding RNA-mediated regulation, are involved in the regulation of gene expression and are crucial for the proper functioning of cells. One of the epigenetic modifiers that has garnered significant attention in recent years is ELP6. In this article, we will discuss the potential implications of ELP6 as a drug target and biomarker.

Structure and Function

ELP6 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression. It is composed of 64 amino acid residues and has a molecular weight of 7.9 kDa. ELP6 is expressed in various tissues and cells, including brain, heart, and cancer cells. It has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

One of the most significant functions of ELP6 is its ability to modify the expression of target genes. It does this by binding to specific DNA sequences and modifying the activity of transcription factors, which in turn control the translation of RNA into protein. This process is known as RNA-protein interaction and is a critical mechanism for the regulation of gene expression.

In addition to its role in gene expression, ELP6 has also been shown to play a critical role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. It has been shown to promote the growth of cancer cells and to contribute to the development of neurodegenerative diseases.

Drug Target Potential

The potential drug targets for ELP6 are vast and varied. One of the most promising targets is its role in the regulation of cancer cell growth. ELP6 has been shown to promote the growth of various types of cancer cells, including breast, lung, and ovarian cancer cells. It has also been shown to contribute to the development of resistance to chemotherapy in cancer cells.

Another potential drug target for ELP6 is its role in the regulation of neurodegenerative diseases. ELP6 has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to promote the neurotoxicity of various drugs, including neurotoxins used in the treatment of these diseases.

Biomarker Potential

ELP6 has also been shown to have potential as a biomarker for various diseases. Its role in the regulation of gene expression makes it an attractive target for the development of diagnostic tests for various diseases. For example, ELP6 has been shown to be involved in the regulation of gene expression in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that ELP6 may be a useful biomarker for these diseases.

In addition to its potential as a drug target, ELP6 has also been shown to have potential as a biomarker for various other diseases. Its role in the regulation of gene expression makes it an attractive target for the development of diagnostic tests for various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.

Conclusion

In conclusion, ELP6 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression and has the potential to be a drug target and biomarker for various diseases. Its role in the regulation of cancer cell growth and neurodegenerative diseases makes it an attractive target for the development of new treatments for these diseases. Further research is needed to fully understand the role of ELP6 in these processes and to develop new diagnostic tests for ELP6.

Protein Name: Elongator Acetyltransferase Complex Subunit 6

Functions: Component of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine) (PubMed:29332244). The elongator complex catalyzes formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (PubMed:22854966, PubMed:29332244). Involved in cell migration (By similarity)

The "ELP6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELP6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets